Company news
AC Immune SA news in 2025
AC Immune SA's news releases, calls and decks from 2025, newest first.
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
December 11, 2025
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
November 11, 2025
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
November 4, 2025
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
October 28, 2025
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
October 24, 2025
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
September 25, 2025
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
September 4, 2025
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
August 5, 2025
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
April 30, 2025
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
April 2, 2025
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
March 25, 2025
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
March 13, 2025
AC Immune to Participate in Upcoming Investor Conferences
March 4, 2025
Decks in 2025
- Shareholder Meeting (June 2025)
Shareholder meeting · 47 slides · Jun 20, 2025